Clinical Trial Update: A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa [Phase 3]

View source ↗

Summary

Phase 3 study evaluating AAV5-hRKp.RPGR for X-linked Retinitis Pigmentosa in Japanese participants is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Retinitis Pigmentosa

Drugs mentioned

• AAV5-hRKp.RPGR

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Retinitis Pigmentosa | Phase 3 | Status: ACTIVE_NOT_RECRUITING